Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy
NCT06960382Phase 2Recruiting
- Sponsor
- University of Zurich
- Start
- Aug 2025
- Primary completion
- May 2027
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of alutard-sq in allergic rhinitis (AR), allergic asthma, sponsored by University of Zurich. Started Aug 2025; status: recruiting.
02
Drugs
alutard-sq
03
Conditions
allergic rhinitis (AR)allergic asthma
Beyond the preview
Go deeper on NCT06960382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06960382.